An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

PET/CT offers excellent accuracy in the staging of high-risk prostate cancer (PCa), yet outcomes-based evidence of the clinical benefit remains limited. We aimed to determine whether the rates of ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard] The latest and most advanced scan for evaluation of patients ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...

Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...

More than 100,000 future cancer cases were projected to result from the 93 million CT examinations performed in 2023, according to a study published April 14 in JAMA Internal Medicine. Low-dose CT ...